CD47 and neoplasm: This enhanced phagocytosis also leads to increased antigen cross-presentation and T cell priming [74], and anti-CD47 therapies have shown synergy with autophagy inhibition [75,76], as well as other ICIs and tumor-specific antibodies [77].